Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,125.86 -13.40 -0.43%
FTSE 100 6,577.61 -6.56 -0.10%
DAX 9,299.52 -18.30 -0.20%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

 Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule

PR Newswire

JERSEY CITY, N.J., March 15, 2013

JERSEY CITY, N.J., March 15, 2013 /PRNewswire/ -- Optimer Pharmaceuticals,
Inc. (NASDAQ: OPTR) announced today that on March 14, 2013 the Compensation,
Nominating, and Corporate Governance Committee of its Board of Directors
approved the grant of inducement restricted stock units covering an aggregate
of 5,010 shares of common stock to 4 new employees.


Each restricted stock unit vests over three years, with one-third of the
shares vesting on the first, second, and third anniversary of the applicable
vesting commencement date, subject to the new employee's continued service
relationship with the Company. Each restricted stock unit is subject to the
terms and conditions of the Company's 2012 Equity Incentive Plan and the
restricted stock unit agreement pursuant to which the award was granted.

The restricted stock units were granted as inducements material to the new
employees entering into employment with Optimer in accordance with NASDAQ
Listing Rule 5635(c)(4).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin)
tablets, an FDA-approved macrolide antibacterial drug for the treatment
of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age
and older and is commercializing DIFICID in the US and Canada.  Optimer also
received marketing authorization for fidaxomicin tablets in the European
Union where its partner, Astellas Pharma Europe, is commercializing
fidaxomicin under the trade name DIFICLIR™.  The Company is exploring
marketing authorization in other parts of the world where C. difficile has
emerged as a serious health problem, including Asia. Additional information
can be found at

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications
Jason I. Spark, Senior Vice President
(619) 849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Sponsored Links
Sponsored Links